aibioGilead cites August 2026 ruling in HIV drug injury suits with about 23,000 active plaintiffs
Tickers GILD
The 10-Q names Gilead as defendant, with no co-defendants listed, in a putative class action and product liability suits over Viread, Truvada, Atripla, Complera and Stribild. A federal bellwether trial is set for March 2027.
Key facts
- Company
- Gilead Sciences, Inc. (NASDAQ: GILD)
- News type
- Legal
- Primary source
- Gilead Sciences 10-Q for the quarter ended June 30, 2026 (SEC EDGAR)
Gilead Sciences, Inc. (Nasdaq: GILD) said in its 10-Q filed August 6, 2026 that the California Supreme Court ruled in its favor in August 2026 in state court product liability litigation over five HIV drugs. The court concluded that plaintiffs' negligence claim could not proceed as a matter of law. The 10-Q puts the number of active plaintiffs at approximately 23,000, in lawsuits pending in state or federal court in California and Missouri. It gives no case names or numbers.
The filings name no defendant other than Gilead. The 10-Q says Gilead has been named as a defendant in one putative class action and various product liability lawsuits, and it lists no co-defendants and no individuals. The claims described here are allegations.
The case
Plaintiffs allege that one or more of Viread, Truvada, Atripla, Complera and Stribild caused them kidney, bone or tooth injuries. They seek damages and other relief on various grounds for alleged personal injury and economic loss. One of the suits is a putative class action pending in Missouri.
Defendants
Gilead. The 10-Q does not name any other company or any officer or director as a defendant in these cases.
Where it stands
In California state court, the first bellwether trial was scheduled to begin in October 2022 but has been stayed pending appellate proceedings in the California Supreme Court. The 10-K filed February 24, 2026 and the 10-Q filed May 7, 2026 both described that stay as still in place. In August 2026, the latest 10-Q says, the Supreme Court ruled in Gilead's favor. It concluded that plaintiffs' negligence claim could not proceed as a matter of law and directed the trial court to enter a new order granting summary judgment for Gilead on all causes of action. The 10-Q does not say how the ruling affects the federal and Missouri cases.
In the California federal case, Gilead agreed to make a one-time payment of approximately $39 million to a group of approximately 2,470 plaintiffs. The federal court set a trial date of March 2027 for the first bellwether trial of the remaining cases.
In the Missouri class action, the district court issued an order in January 2026 denying, among other things, plaintiffs' motion for class certification. The 10-K said plaintiffs had petitioned the Eighth Circuit for appellate review. The 10-Q says the Eighth Circuit then denied the request for interlocutory review of the class certification decision.
Why it matters to shareholders
Gilead says it intends to defend the actions vigorously and cannot predict the outcome. If plaintiffs succeed, it says, it could be required to pay significant monetary damages, which may materially and adversely affect its results of operations and financial condition in the period when an outcome becomes probable and estimable.
The company reports no material accruals for the matters in this note as of June 30, 2026 and December 31, 2025. In its risk factors Gilead says it has limited insurance for product liabilities and that claims may exceed its coverage.
Related matters
The same note describes other litigation. Gilead sued Cipla Ltd. in the U.S. District Court for the District of Delaware in February 2026 over Cipla's 505(b)(2) application referencing Descovy. HIV antitrust class actions are pending in the Northern District of California. A qui tam suit in the Eastern District of Pennsylvania was dismissed on summary judgment in September 2025 and is on appeal. A Texas qui tam case, in which the Texas Attorney General has intervened, has a trial scheduled for December 2026.